专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130253135A1 POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES 有权
标题翻译：用于交付寡核苷酸的聚（酰胺）聚合物
公开(公告)号：US20130253135A1
公开(公告)日：2013-09-26
申请号：US13885737
申请日：2011-11-16
申请人： Stephanie E. Barrett , Marina Busuek , Steven L. Colletti , Robert M. Garbaccio , Erin N. Guidry , Robert A. Kowtoniuk , Jing Liao , Craig A. Parish , Rubina G. Parmar , Tao Pei , Kevin M. Schlosser , David M. Tellers , Sandra C. Tobias , Quang T. Truong , Jacob H. Waldman , Weimin Wang , J. Michael Williams
发明人： Stephanie E. Barrett , Marina Busuek , Steven L. Colletti , Robert M. Garbaccio , Erin N. Guidry , Robert A. Kowtoniuk , Jing Liao , Craig A. Parish , Rubina G. Parmar , Tao Pei , Kevin M. Schlosser , David M. Tellers , Sandra C. Tobias , Quang T. Truong , Jacob H. Waldman , Weimin Wang , J. Michael Williams
IPC分类号： A61K47/48
CPC分类号： A61K47/48092 , A61K47/549 , C08G69/10 , C08G73/028 , C08L79/02
摘要： The present invention provides poly(amide) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.
摘要翻译：本发明提供用于递送用于治疗目的的寡核苷酸的聚（酰胺）聚合物，多偶联物，组合物和方法。

2. 发明授权

US11702430B2 Aza-benzothiophene compounds as STING agonists 有权
公开(公告)号：US11702430B2
公开(公告)日：2023-07-18
申请号：US17040192
申请日：2019-03-28
申请人： Merck Sharp & Dohme LLC , Michael D. Altman , Brandon D. Cash , Jared N. Cumming , Duane E. DeMong , Andrew M. Haidle , James P. Jewell , Matthew A. Larsen , Min Lu , Ryan D. Otte , Brandon M. Taoka , Benjamin Wesley Trotter , Quang T. Truong
发明人： Michael D. Altman , Brandon D. Cash , Jared N. Cumming , Duane E. DeMong , Andrew M. Haidle , James P. Jewell , Matthew A. Larsen , Min Lu , Ryan D. Otte , Brandon M. Taoka , Benjamin Wesley Trotter , Quang T. Truong
IPC分类号： C07D513/04 , C07D495/04 , C07D277/64 , A61P37/04 , A61P35/00
CPC分类号： C07D513/04 , A61P37/04 , C07D495/04
摘要： Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

3. 发明申请

US20210009608A1 AZA-BENZOTHIOPHENE COMPOUNDS AS STING AGONISTS 有权
公开(公告)号：US20210009608A1
公开(公告)日：2021-01-14
申请号：US17040192
申请日：2019-03-28
申请人： Michael D. ALTMAN , Brandon D. CASH , Jared N. CUMMING , Duane E. DEMONG , Andrew M. HAIDLE , James P. JEWELL , Matthew A. LARSEN , Min LU , Ryan D. OTTE , Brandon M. TAOKA , Benjamin Wesley TROTTER , Quang T, TRUONG , Merck Sharp & Dohme Corp.
发明人： Michael D. Altman , Brandon D. Cash , Jared N. Cumming , Duane E. DeMong , Andrew M. Haidle , James P. Jewell , Matthew A. Larsen , Min Lu , Ryan D. Otte , Brandon M. Taoka , Benjamin Wesley Trotter , Quang T. Truong
IPC分类号： C07D513/04 , C07D495/04 , A61P37/04
摘要： Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

4. 发明申请

US20100184758A1 BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS 审中-公开
标题翻译：作为抗菌化合物的碳氢化合物衍生物
公开(公告)号：US20100184758A1
公开(公告)日：2010-07-22
申请号：US12668822
申请日：2008-07-15
申请人： Peter H. Dobbelaar , Wu Du , Liangqin Guo , William K. Hagmann , Shuwen He , Tianying Jian , Jian Liu , Ravi P. Nargund , Alexander Pasternak , Shrenik K. Shah , Quang T. Truong , Zhixiong Ye , James Deliureficio , Raman Bakshi
发明人： Peter H. Dobbelaar , Wu Du , Liangqin Guo , William K. Hagmann , Shuwen He , Tianying Jian , Jian Liu , Ravi P. Nargund , Alexander Pasternak , Shrenik K. Shah , Quang T. Truong , Zhixiong Ye , James Deliureficio , Raman Bakshi
IPC分类号： A61K31/5377 , C07D471/14 , A61K31/437 , C07D413/14 , C07D403/14 , A61K31/501 , A61K31/4995 , A61K31/506 , A61P3/10 , A61P3/04 , A61P3/00 , A61P3/06 , A61P9/12
CPC分类号： C07D471/04
摘要： Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.
摘要翻译：结构式I的β-咔啉衍生物是生长抑素亚型受体3（SSTR3）的选择性拮抗剂，可用于治疗2型糖尿病和通常与该疾病相关的病症，包括高血糖症，胰岛素抵抗，肥胖症，脂质障碍和高血压。这些化合物也可用于治疗抑郁症和焦虑症。

5. 发明申请

US20180230178A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS 审中-公开
公开(公告)号：US20180230178A1
公开(公告)日：2018-08-16
申请号：US15752144
申请日：2016-08-11
申请人： Michael D. ALTMAN , Brian ANDRESEN , Wonsuk CHANG , Matthew Lloyd CHILDERS , Jared N. CUMMING , Andrew Marc HAIDLE , Timothy J. HENDERSON , James P. JEWELL , Min LU , Alan B. NORTHRUP , Ryan D. OTTE , Tony SIU , Benjamin Wesley TROTTER , Quang T TRUONG , Merck Sharp & Dohme Corp.
发明人： Michael D. Altman , Brian Andresen , Wonsuk Chang , Matthew Lloyd Childers , Jared N. Cumming , Andrew Marc Haidle , Timothy J. Henderson , James P. Jewell , Min Lu , Alan B. Northrup , Ryan D. Otte , Tony Siu , Benjamin Wesley Trotter , Quang T. Truong
IPC分类号： C07H21/04 , C07H21/02 , C07H19/23 , C07H19/20 , A61P35/00
摘要： A class of polycyclic compounds of general formula (II), of general formula (II′), or of general formula (II″), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

6. 发明申请

US20140128339A1 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 审中-公开
标题翻译： 2'-甲基取代的核苷衍生物及其用于治疗病毒性疾病的方法
公开(公告)号：US20140128339A1
公开(公告)日：2014-05-08
申请号：US14054424
申请日：2013-10-15
申请人： Vinay Girijavallabhan , Stephane Bogen , Quang T. Truong , Ping Chen , Angela Kerekes , Frank Bennett , Sara Esposite , Qingmei Hong , Ian Davies
发明人： Vinay Girijavallabhan , Stephane Bogen , Quang T. Truong , Ping Chen , Angela Kerekes , Frank Bennett , Sara Esposite , Qingmei Hong , Ian Davies
IPC分类号： C07H19/06 , A61K45/06 , A61K31/7072 , C07H19/10 , A61K31/7068
CPC分类号： C07H19/06 , A61K31/7068 , A61K31/7072 , A61K45/06 , C07H19/067 , C07H19/073 , C07H19/10
摘要： The present invention relates to 2′-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3, are as defined herein. The present invention also relates to compositions comprising at least one 2′-Methyl Substituted Nucleoside Derivative, and methods of using the 2′-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
摘要翻译：本发明涉及式（I）的2'-甲基取代的核苷衍生物及其药学上可接受的盐，其中R，R 1，R 2和R 3如本文所定义。本发明还涉及包含至少一种2'-甲基取代的核苷衍生物的组合物，以及使用2'-甲基取代的核苷衍生物治疗或预防患者HCV感染的方法。

7. 发明申请

US20120264777A1 OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS 有权
标题翻译：作为抗菌化合物的奥沙唑苯甲酰胺衍生物
公开(公告)号：US20120264777A1
公开(公告)日：2012-10-18
申请号：US13518015
申请日：2011-01-11
申请人： Liangqin Guo , William K. Hagmann , Shuwen He , Zhong Lai , Jian Liu , Ravi P. Nargund , Shrenik K. Shah , Quang T. Truong
发明人： Liangqin Guo , William K. Hagmann , Shuwen He , Zhong Lai , Jian Liu , Ravi P. Nargund , Shrenik K. Shah , Quang T. Truong
IPC分类号： A61K31/437 , A61P3/10 , A61P9/12 , A61P3/04 , A61P3/06 , A61P3/00 , C07D471/04 , A61P5/48
CPC分类号： C07D471/04
摘要： Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin sub-type receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.
摘要翻译：结构式I的β-咔啉衍生物是生长抑素亚型受体3（SSTR3）的选择性拮抗剂，可用于治疗2型糖尿病和通常与该疾病相关的病症，包括高血糖症，胰岛素抵抗，肥胖，脂质障碍和高血压。这些化合物也可用于治疗抑郁症和焦虑症。

8. 发明授权

US10738074B2 Cyclic di-nucleotide compounds as STING agonists 有权
公开(公告)号：US10738074B2
公开(公告)日：2020-08-11
申请号：US15752144
申请日：2016-08-11
申请人： Merck Sharp & Dohme Corp. , Michael D. Altman , Brian Andresen , Wonsuk Chang , Matthew Lloyd Childers , Jared N. Cumming , Andrew Marc Haidle , Timothy J. Henderson , James P. Jewell , Min Lu , Alan B. Northrup , Ryan D. Otte , Tony Siu , Benjamin Wesley Trotter , Quang T. Truong
发明人： Michael D. Altman , Brian Andresen , Wonsuk Chang , Matthew Lloyd Childers , Jared N. Cumming , Andrew Marc Haidle , Timothy J. Henderson , James P. Jewell , Min Lu , Alan B. Northrup , Ryan D. Otte , Tony Siu , Benjamin Wesley Trotter , Quang T. Truong
IPC分类号： A01N43/04 , A61K31/70 , C07H21/04 , C07H21/02 , A61K39/39 , C07H19/20 , C07H19/23 , C07H21/00 , A61P35/00 , A61K31/7064 , A61K31/7084 , A61K31/708 , A61K31/706 , A61K31/7076
摘要： A class of polycyclic compounds of general formula (II), of general formula (II′), or of general formula (II″), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

9. 发明授权

US08754099B2 Oxadiazole beta carboline derivatives as antidiabetic compounds 有权
标题翻译：恶二唑β咔啉衍生物作为抗糖尿病化合物
公开(公告)号：US08754099B2
公开(公告)日：2014-06-17
申请号：US13518015
申请日：2011-01-11
申请人： Liangqin Guo , William K. Hagmann , Shuwen He , Zhong Lai , Jian Liu , Ravi P. Nargund , Shrenik K. Shah , Quang T. Truong
发明人： Liangqin Guo , William K. Hagmann , Shuwen He , Zhong Lai , Jian Liu , Ravi P. Nargund , Shrenik K. Shah , Quang T. Truong
IPC分类号： A61K31/44
CPC分类号： C07D471/04
摘要： Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.
摘要翻译：结构式I的β-咔啉衍生物是生长抑素亚型受体3（SSTR3）的选择性拮抗剂，可用于治疗2型糖尿病和通常与该疾病相关的病症，包括高血糖症，胰岛素抵抗，肥胖症，脂质障碍和高血压。这些化合物也可用于治疗抑郁症和焦虑症。

10. 发明授权

US07572785B2 Substituted imidazoles as cannabinoid receptor modulators 失效
标题翻译：取代的咪唑作为大麻素受体调节剂
公开(公告)号：US07572785B2
公开(公告)日：2009-08-11
申请号：US11265850
申请日：2005-11-03
申请人： Paul E. Finke , Sander G. Mills , Christopher W. Plummer , Shrenik K. Shah , Quang T. Truong
发明人： Paul E. Finke , Sander G. Mills , Christopher W. Plummer , Shrenik K. Shah , Quang T. Truong
IPC分类号： A61K31/55 , C07D405/00 , C07D413/00
CPC分类号： C07D405/12 , C07D233/90
摘要： The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.
摘要翻译：使用本发明的化合物作为大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，特别是用于治疗，预防和抑制由大麻素-1（CB1）受体介导的疾病。本发明涉及这些新化合物选择性拮抗大麻素-1（CB1）受体的用途。因此，本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的精神药物。血管意外和头部创伤，焦虑障碍，压力，癫痫，帕金森病和精神分裂症。这些化合物也可用于治疗药物滥用障碍，特别是鸦片剂，酒精和尼古丁。所述化合物还可用于治疗与过量食物摄入和与其相关的并发症相关的肥胖或进食障碍。还要求新的结构式（I）化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式